INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1401, 3008, 'Lamotrigine', 'Liver Diseases', 'Lamotrigine is primarily converted by the liver to inactive glucuronide metabolites and subsequently eliminated by the kidney.  Approximately 10% of a dose is excreted in the urine as unchanged drug.  The plasma clearance of lamotrigine may be decreased and the half-life prolonged in patients with impaired renal and/or hepatic function.  However, clinical data are limited.  In a comparison of 12 healthy subjects and 24 with various degrees of liver disease, lamotrigine pharmacokinetics were significantly altered only in patients with severe cirrhosis.  Therapy with lamotrigine should be administered cautiously and at reduced dosages in such patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1402, 3010, 'Lamotrigine', 'Liver Diseases', 'Lamotrigine is primarily converted by the liver to inactive glucuronide metabolites and subsequently eliminated by the kidney.  Approximately 10% of a dose is excreted in the urine as unchanged drug.  The plasma clearance of lamotrigine may be decreased and the half-life prolonged in patients with impaired renal and/or hepatic function.  However, clinical data are limited.  In a comparison of 12 healthy subjects and 24 with various degrees of liver disease, lamotrigine pharmacokinetics were significantly altered only in patients with severe cirrhosis.  Therapy with lamotrigine should be administered cautiously and at reduced dosages in such patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1403, 3011, 'Lamotrigine', 'Liver Diseases', 'Lamotrigine is primarily converted by the liver to inactive glucuronide metabolites and subsequently eliminated by the kidney.  Approximately 10% of a dose is excreted in the urine as unchanged drug.  The plasma clearance of lamotrigine may be decreased and the half-life prolonged in patients with impaired renal and/or hepatic function.  However, clinical data are limited.  In a comparison of 12 healthy subjects and 24 with various degrees of liver disease, lamotrigine pharmacokinetics were significantly altered only in patients with severe cirrhosis.  Therapy with lamotrigine should be administered cautiously and at reduced dosages in such patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1404, 4022, 'Lamotrigine', 'Liver Diseases', 'Lamotrigine is primarily converted by the liver to inactive glucuronide metabolites and subsequently eliminated by the kidney.  Approximately 10% of a dose is excreted in the urine as unchanged drug.  The plasma clearance of lamotrigine may be decreased and the half-life prolonged in patients with impaired renal and/or hepatic function.  However, clinical data are limited.  In a comparison of 12 healthy subjects and 24 with various degrees of liver disease, lamotrigine pharmacokinetics were significantly altered only in patients with severe cirrhosis.  Therapy with lamotrigine should be administered cautiously and at reduced dosages in such patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1405, 4024, 'Lamotrigine', 'Liver Diseases', 'Lamotrigine is primarily converted by the liver to inactive glucuronide metabolites and subsequently eliminated by the kidney.  Approximately 10% of a dose is excreted in the urine as unchanged drug.  The plasma clearance of lamotrigine may be decreased and the half-life prolonged in patients with impaired renal and/or hepatic function.  However, clinical data are limited.  In a comparison of 12 healthy subjects and 24 with various degrees of liver disease, lamotrigine pharmacokinetics were significantly altered only in patients with severe cirrhosis.  Therapy with lamotrigine should be administered cautiously and at reduced dosages in such patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1406, 4032, 'Lamotrigine', 'Liver Diseases', 'Lamotrigine is primarily converted by the liver to inactive glucuronide metabolites and subsequently eliminated by the kidney.  Approximately 10% of a dose is excreted in the urine as unchanged drug.  The plasma clearance of lamotrigine may be decreased and the half-life prolonged in patients with impaired renal and/or hepatic function.  However, clinical data are limited.  In a comparison of 12 healthy subjects and 24 with various degrees of liver disease, lamotrigine pharmacokinetics were significantly altered only in patients with severe cirrhosis.  Therapy with lamotrigine should be administered cautiously and at reduced dosages in such patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1407, 7074, 'Lamotrigine', 'Liver Diseases', 'Lamotrigine is primarily converted by the liver to inactive glucuronide metabolites and subsequently eliminated by the kidney.  Approximately 10% of a dose is excreted in the urine as unchanged drug.  The plasma clearance of lamotrigine may be decreased and the half-life prolonged in patients with impaired renal and/or hepatic function.  However, clinical data are limited.  In a comparison of 12 healthy subjects and 24 with various degrees of liver disease, lamotrigine pharmacokinetics were significantly altered only in patients with severe cirrhosis.  Therapy with lamotrigine should be administered cautiously and at reduced dosages in such patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1408, 7075, 'Lamotrigine', 'Liver Diseases', 'Lamotrigine is primarily converted by the liver to inactive glucuronide metabolites and subsequently eliminated by the kidney.  Approximately 10% of a dose is excreted in the urine as unchanged drug.  The plasma clearance of lamotrigine may be decreased and the half-life prolonged in patients with impaired renal and/or hepatic function.  However, clinical data are limited.  In a comparison of 12 healthy subjects and 24 with various degrees of liver disease, lamotrigine pharmacokinetics were significantly altered only in patients with severe cirrhosis.  Therapy with lamotrigine should be administered cautiously and at reduced dosages in such patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1409, 7088, 'Lamotrigine', 'Liver Diseases', 'Lamotrigine is primarily converted by the liver to inactive glucuronide metabolites and subsequently eliminated by the kidney.  Approximately 10% of a dose is excreted in the urine as unchanged drug.  The plasma clearance of lamotrigine may be decreased and the half-life prolonged in patients with impaired renal and/or hepatic function.  However, clinical data are limited.  In a comparison of 12 healthy subjects and 24 with various degrees of liver disease, lamotrigine pharmacokinetics were significantly altered only in patients with severe cirrhosis.  Therapy with lamotrigine should be administered cautiously and at reduced dosages in such patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1410, 7089, 'Lamotrigine', 'Liver Diseases', 'Lamotrigine is primarily converted by the liver to inactive glucuronide metabolites and subsequently eliminated by the kidney.  Approximately 10% of a dose is excreted in the urine as unchanged drug.  The plasma clearance of lamotrigine may be decreased and the half-life prolonged in patients with impaired renal and/or hepatic function.  However, clinical data are limited.  In a comparison of 12 healthy subjects and 24 with various degrees of liver disease, lamotrigine pharmacokinetics were significantly altered only in patients with severe cirrhosis.  Therapy with lamotrigine should be administered cautiously and at reduced dosages in such patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1411, 7090, 'Lamotrigine', 'Liver Diseases', 'Lamotrigine is primarily converted by the liver to inactive glucuronide metabolites and subsequently eliminated by the kidney.  Approximately 10% of a dose is excreted in the urine as unchanged drug.  The plasma clearance of lamotrigine may be decreased and the half-life prolonged in patients with impaired renal and/or hepatic function.  However, clinical data are limited.  In a comparison of 12 healthy subjects and 24 with various degrees of liver disease, lamotrigine pharmacokinetics were significantly altered only in patients with severe cirrhosis.  Therapy with lamotrigine should be administered cautiously and at reduced dosages in such patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1412, 7091, 'Lamotrigine', 'Liver Diseases', 'Lamotrigine is primarily converted by the liver to inactive glucuronide metabolites and subsequently eliminated by the kidney.  Approximately 10% of a dose is excreted in the urine as unchanged drug.  The plasma clearance of lamotrigine may be decreased and the half-life prolonged in patients with impaired renal and/or hepatic function.  However, clinical data are limited.  In a comparison of 12 healthy subjects and 24 with various degrees of liver disease, lamotrigine pharmacokinetics were significantly altered only in patients with severe cirrhosis.  Therapy with lamotrigine should be administered cautiously and at reduced dosages in such patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1413, 7114, 'Lamotrigine', 'Liver Diseases', 'Lamotrigine is primarily converted by the liver to inactive glucuronide metabolites and subsequently eliminated by the kidney.  Approximately 10% of a dose is excreted in the urine as unchanged drug.  The plasma clearance of lamotrigine may be decreased and the half-life prolonged in patients with impaired renal and/or hepatic function.  However, clinical data are limited.  In a comparison of 12 healthy subjects and 24 with various degrees of liver disease, lamotrigine pharmacokinetics were significantly altered only in patients with severe cirrhosis.  Therapy with lamotrigine should be administered cautiously and at reduced dosages in such patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1414, 7206, 'Lamotrigine', 'Liver Diseases', 'Lamotrigine is primarily converted by the liver to inactive glucuronide metabolites and subsequently eliminated by the kidney.  Approximately 10% of a dose is excreted in the urine as unchanged drug.  The plasma clearance of lamotrigine may be decreased and the half-life prolonged in patients with impaired renal and/or hepatic function.  However, clinical data are limited.  In a comparison of 12 healthy subjects and 24 with various degrees of liver disease, lamotrigine pharmacokinetics were significantly altered only in patients with severe cirrhosis.  Therapy with lamotrigine should be administered cautiously and at reduced dosages in such patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1415, 21509, 'Lamotrigine', 'Liver Diseases', 'Lamotrigine is primarily converted by the liver to inactive glucuronide metabolites and subsequently eliminated by the kidney.  Approximately 10% of a dose is excreted in the urine as unchanged drug.  The plasma clearance of lamotrigine may be decreased and the half-life prolonged in patients with impaired renal and/or hepatic function.  However, clinical data are limited.  In a comparison of 12 healthy subjects and 24 with various degrees of liver disease, lamotrigine pharmacokinetics were significantly altered only in patients with severe cirrhosis.  Therapy with lamotrigine should be administered cautiously and at reduced dosages in such patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1416, 21510, 'Lamotrigine', 'Liver Diseases', 'Lamotrigine is primarily converted by the liver to inactive glucuronide metabolites and subsequently eliminated by the kidney.  Approximately 10% of a dose is excreted in the urine as unchanged drug.  The plasma clearance of lamotrigine may be decreased and the half-life prolonged in patients with impaired renal and/or hepatic function.  However, clinical data are limited.  In a comparison of 12 healthy subjects and 24 with various degrees of liver disease, lamotrigine pharmacokinetics were significantly altered only in patients with severe cirrhosis.  Therapy with lamotrigine should be administered cautiously and at reduced dosages in such patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1417, 21560, 'Lamotrigine', 'Liver Diseases', 'Lamotrigine is primarily converted by the liver to inactive glucuronide metabolites and subsequently eliminated by the kidney.  Approximately 10% of a dose is excreted in the urine as unchanged drug.  The plasma clearance of lamotrigine may be decreased and the half-life prolonged in patients with impaired renal and/or hepatic function.  However, clinical data are limited.  In a comparison of 12 healthy subjects and 24 with various degrees of liver disease, lamotrigine pharmacokinetics were significantly altered only in patients with severe cirrhosis.  Therapy with lamotrigine should be administered cautiously and at reduced dosages in such patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1418, 21561, 'Lamotrigine', 'Liver Diseases', 'Lamotrigine is primarily converted by the liver to inactive glucuronide metabolites and subsequently eliminated by the kidney.  Approximately 10% of a dose is excreted in the urine as unchanged drug.  The plasma clearance of lamotrigine may be decreased and the half-life prolonged in patients with impaired renal and/or hepatic function.  However, clinical data are limited.  In a comparison of 12 healthy subjects and 24 with various degrees of liver disease, lamotrigine pharmacokinetics were significantly altered only in patients with severe cirrhosis.  Therapy with lamotrigine should be administered cautiously and at reduced dosages in such patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1419, 21583, 'Lamotrigine', 'Liver Diseases', 'Lamotrigine is primarily converted by the liver to inactive glucuronide metabolites and subsequently eliminated by the kidney.  Approximately 10% of a dose is excreted in the urine as unchanged drug.  The plasma clearance of lamotrigine may be decreased and the half-life prolonged in patients with impaired renal and/or hepatic function.  However, clinical data are limited.  In a comparison of 12 healthy subjects and 24 with various degrees of liver disease, lamotrigine pharmacokinetics were significantly altered only in patients with severe cirrhosis.  Therapy with lamotrigine should be administered cautiously and at reduced dosages in such patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1420, 21616, 'Lamotrigine', 'Liver Diseases', 'Lamotrigine is primarily converted by the liver to inactive glucuronide metabolites and subsequently eliminated by the kidney.  Approximately 10% of a dose is excreted in the urine as unchanged drug.  The plasma clearance of lamotrigine may be decreased and the half-life prolonged in patients with impaired renal and/or hepatic function.  However, clinical data are limited.  In a comparison of 12 healthy subjects and 24 with various degrees of liver disease, lamotrigine pharmacokinetics were significantly altered only in patients with severe cirrhosis.  Therapy with lamotrigine should be administered cautiously and at reduced dosages in such patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1421, 21710, 'Lamotrigine', 'Liver Diseases', 'Lamotrigine is primarily converted by the liver to inactive glucuronide metabolites and subsequently eliminated by the kidney.  Approximately 10% of a dose is excreted in the urine as unchanged drug.  The plasma clearance of lamotrigine may be decreased and the half-life prolonged in patients with impaired renal and/or hepatic function.  However, clinical data are limited.  In a comparison of 12 healthy subjects and 24 with various degrees of liver disease, lamotrigine pharmacokinetics were significantly altered only in patients with severe cirrhosis.  Therapy with lamotrigine should be administered cautiously and at reduced dosages in such patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1422, 26360, 'Lamotrigine', 'Liver Diseases', 'Lamotrigine is primarily converted by the liver to inactive glucuronide metabolites and subsequently eliminated by the kidney.  Approximately 10% of a dose is excreted in the urine as unchanged drug.  The plasma clearance of lamotrigine may be decreased and the half-life prolonged in patients with impaired renal and/or hepatic function.  However, clinical data are limited.  In a comparison of 12 healthy subjects and 24 with various degrees of liver disease, lamotrigine pharmacokinetics were significantly altered only in patients with severe cirrhosis.  Therapy with lamotrigine should be administered cautiously and at reduced dosages in such patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1423, 3008, 'Lamotrigine', 'Phenylketonurias', 'Lamotrigine tablets for oral suspension (chewable dispersible tablets) contain phenylalanine.  The phenylalanine content should be considered when these products are used in patients who must restrict their intake of phenylalanine (i.e.  phenylketonurics).', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1424, 3010, 'Lamotrigine', 'Phenylketonurias', 'Lamotrigine tablets for oral suspension (chewable dispersible tablets) contain phenylalanine.  The phenylalanine content should be considered when these products are used in patients who must restrict their intake of phenylalanine (i.e.  phenylketonurics).', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1425, 3011, 'Lamotrigine', 'Phenylketonurias', 'Lamotrigine tablets for oral suspension (chewable dispersible tablets) contain phenylalanine.  The phenylalanine content should be considered when these products are used in patients who must restrict their intake of phenylalanine (i.e.  phenylketonurics).', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1426, 4022, 'Lamotrigine', 'Phenylketonurias', 'Lamotrigine tablets for oral suspension (chewable dispersible tablets) contain phenylalanine.  The phenylalanine content should be considered when these products are used in patients who must restrict their intake of phenylalanine (i.e.  phenylketonurics).', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1427, 4024, 'Lamotrigine', 'Phenylketonurias', 'Lamotrigine tablets for oral suspension (chewable dispersible tablets) contain phenylalanine.  The phenylalanine content should be considered when these products are used in patients who must restrict their intake of phenylalanine (i.e.  phenylketonurics).', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1428, 4032, 'Lamotrigine', 'Phenylketonurias', 'Lamotrigine tablets for oral suspension (chewable dispersible tablets) contain phenylalanine.  The phenylalanine content should be considered when these products are used in patients who must restrict their intake of phenylalanine (i.e.  phenylketonurics).', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1429, 7074, 'Lamotrigine', 'Phenylketonurias', 'Lamotrigine tablets for oral suspension (chewable dispersible tablets) contain phenylalanine.  The phenylalanine content should be considered when these products are used in patients who must restrict their intake of phenylalanine (i.e.  phenylketonurics).', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1430, 7075, 'Lamotrigine', 'Phenylketonurias', 'Lamotrigine tablets for oral suspension (chewable dispersible tablets) contain phenylalanine.  The phenylalanine content should be considered when these products are used in patients who must restrict their intake of phenylalanine (i.e.  phenylketonurics).', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1431, 7088, 'Lamotrigine', 'Phenylketonurias', 'Lamotrigine tablets for oral suspension (chewable dispersible tablets) contain phenylalanine.  The phenylalanine content should be considered when these products are used in patients who must restrict their intake of phenylalanine (i.e.  phenylketonurics).', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1432, 7089, 'Lamotrigine', 'Phenylketonurias', 'Lamotrigine tablets for oral suspension (chewable dispersible tablets) contain phenylalanine.  The phenylalanine content should be considered when these products are used in patients who must restrict their intake of phenylalanine (i.e.  phenylketonurics).', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1433, 7090, 'Lamotrigine', 'Phenylketonurias', 'Lamotrigine tablets for oral suspension (chewable dispersible tablets) contain phenylalanine.  The phenylalanine content should be considered when these products are used in patients who must restrict their intake of phenylalanine (i.e.  phenylketonurics).', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1434, 7091, 'Lamotrigine', 'Phenylketonurias', 'Lamotrigine tablets for oral suspension (chewable dispersible tablets) contain phenylalanine.  The phenylalanine content should be considered when these products are used in patients who must restrict their intake of phenylalanine (i.e.  phenylketonurics).', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1435, 7114, 'Lamotrigine', 'Phenylketonurias', 'Lamotrigine tablets for oral suspension (chewable dispersible tablets) contain phenylalanine.  The phenylalanine content should be considered when these products are used in patients who must restrict their intake of phenylalanine (i.e.  phenylketonurics).', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1436, 7206, 'Lamotrigine', 'Phenylketonurias', 'Lamotrigine tablets for oral suspension (chewable dispersible tablets) contain phenylalanine.  The phenylalanine content should be considered when these products are used in patients who must restrict their intake of phenylalanine (i.e.  phenylketonurics).', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1437, 21509, 'Lamotrigine', 'Phenylketonurias', 'Lamotrigine tablets for oral suspension (chewable dispersible tablets) contain phenylalanine.  The phenylalanine content should be considered when these products are used in patients who must restrict their intake of phenylalanine (i.e.  phenylketonurics).', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1438, 21510, 'Lamotrigine', 'Phenylketonurias', 'Lamotrigine tablets for oral suspension (chewable dispersible tablets) contain phenylalanine.  The phenylalanine content should be considered when these products are used in patients who must restrict their intake of phenylalanine (i.e.  phenylketonurics).', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1439, 21560, 'Lamotrigine', 'Phenylketonurias', 'Lamotrigine tablets for oral suspension (chewable dispersible tablets) contain phenylalanine.  The phenylalanine content should be considered when these products are used in patients who must restrict their intake of phenylalanine (i.e.  phenylketonurics).', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1440, 21561, 'Lamotrigine', 'Phenylketonurias', 'Lamotrigine tablets for oral suspension (chewable dispersible tablets) contain phenylalanine.  The phenylalanine content should be considered when these products are used in patients who must restrict their intake of phenylalanine (i.e.  phenylketonurics).', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1441, 21583, 'Lamotrigine', 'Phenylketonurias', 'Lamotrigine tablets for oral suspension (chewable dispersible tablets) contain phenylalanine.  The phenylalanine content should be considered when these products are used in patients who must restrict their intake of phenylalanine (i.e.  phenylketonurics).', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1442, 21616, 'Lamotrigine', 'Phenylketonurias', 'Lamotrigine tablets for oral suspension (chewable dispersible tablets) contain phenylalanine.  The phenylalanine content should be considered when these products are used in patients who must restrict their intake of phenylalanine (i.e.  phenylketonurics).', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1443, 21710, 'Lamotrigine', 'Phenylketonurias', 'Lamotrigine tablets for oral suspension (chewable dispersible tablets) contain phenylalanine.  The phenylalanine content should be considered when these products are used in patients who must restrict their intake of phenylalanine (i.e.  phenylketonurics).', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1444, 26360, 'Lamotrigine', 'Phenylketonurias', 'Lamotrigine tablets for oral suspension (chewable dispersible tablets) contain phenylalanine.  The phenylalanine content should be considered when these products are used in patients who must restrict their intake of phenylalanine (i.e.  phenylketonurics).', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1445, 7051, 'Lactulose', 'Galactosemias', 'Since lactulose solution contains galactose, use is contraindicated in patients who require a low galactose diet.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1446, 7061, 'Lactulose', 'Galactosemias', 'Since lactulose solution contains galactose, use is contraindicated in patients who require a low galactose diet.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1447, 10242, 'Lactulose', 'Galactosemias', 'Since lactulose solution contains galactose, use is contraindicated in patients who require a low galactose diet.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1448, 17961, 'Lactulose', 'Galactosemias', 'Since lactulose solution contains galactose, use is contraindicated in patients who require a low galactose diet.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1449, 17962, 'Lactulose', 'Galactosemias', 'Since lactulose solution contains galactose, use is contraindicated in patients who require a low galactose diet.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1450, 18804, 'Lactulose', 'Galactosemias', 'Since lactulose solution contains galactose, use is contraindicated in patients who require a low galactose diet.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1451, 21541, 'Lactulose', 'Galactosemias', 'Since lactulose solution contains galactose, use is contraindicated in patients who require a low galactose diet.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1452, 21545, 'Lactulose', 'Galactosemias', 'Since lactulose solution contains galactose, use is contraindicated in patients who require a low galactose diet.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1453, 21547, 'Lactulose', 'Galactosemias', 'Since lactulose solution contains galactose, use is contraindicated in patients who require a low galactose diet.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1454, 21551, 'Lactulose', 'Galactosemias', 'Since lactulose solution contains galactose, use is contraindicated in patients who require a low galactose diet.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1455, 21655, 'Lactulose', 'Galactosemias', 'Since lactulose solution contains galactose, use is contraindicated in patients who require a low galactose diet.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1456, 21656, 'Lactulose', 'Galactosemias', 'Since lactulose solution contains galactose, use is contraindicated in patients who require a low galactose diet.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1457, 26675, 'Lactulose', 'Galactosemias', 'Since lactulose solution contains galactose, use is contraindicated in patients who require a low galactose diet.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1458, 29352, 'Lactulose', 'Galactosemias', 'Since lactulose solution contains galactose, use is contraindicated in patients who require a low galactose diet.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1459, 29353, 'Lactulose', 'Galactosemias', 'Since lactulose solution contains galactose, use is contraindicated in patients who require a low galactose diet.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1460, 33077, 'Lactulose', 'Galactosemias', 'Since lactulose solution contains galactose, use is contraindicated in patients who require a low galactose diet.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1461, 7051, 'Lactulose', 'Inflammatory Bowel Diseases', 'The use of laxatives is contraindicated in patients with inflammatory bowel disease.  Patients with inflammatory bowel disease may experience colonic perforation with use of stimulant laxatives.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1462, 7061, 'Lactulose', 'Inflammatory Bowel Diseases', 'The use of laxatives is contraindicated in patients with inflammatory bowel disease.  Patients with inflammatory bowel disease may experience colonic perforation with use of stimulant laxatives.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1463, 10242, 'Lactulose', 'Inflammatory Bowel Diseases', 'The use of laxatives is contraindicated in patients with inflammatory bowel disease.  Patients with inflammatory bowel disease may experience colonic perforation with use of stimulant laxatives.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1464, 17961, 'Lactulose', 'Inflammatory Bowel Diseases', 'The use of laxatives is contraindicated in patients with inflammatory bowel disease.  Patients with inflammatory bowel disease may experience colonic perforation with use of stimulant laxatives.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1465, 17962, 'Lactulose', 'Inflammatory Bowel Diseases', 'The use of laxatives is contraindicated in patients with inflammatory bowel disease.  Patients with inflammatory bowel disease may experience colonic perforation with use of stimulant laxatives.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1466, 18804, 'Lactulose', 'Inflammatory Bowel Diseases', 'The use of laxatives is contraindicated in patients with inflammatory bowel disease.  Patients with inflammatory bowel disease may experience colonic perforation with use of stimulant laxatives.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1467, 21541, 'Lactulose', 'Inflammatory Bowel Diseases', 'The use of laxatives is contraindicated in patients with inflammatory bowel disease.  Patients with inflammatory bowel disease may experience colonic perforation with use of stimulant laxatives.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1468, 21545, 'Lactulose', 'Inflammatory Bowel Diseases', 'The use of laxatives is contraindicated in patients with inflammatory bowel disease.  Patients with inflammatory bowel disease may experience colonic perforation with use of stimulant laxatives.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1469, 21547, 'Lactulose', 'Inflammatory Bowel Diseases', 'The use of laxatives is contraindicated in patients with inflammatory bowel disease.  Patients with inflammatory bowel disease may experience colonic perforation with use of stimulant laxatives.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1470, 21551, 'Lactulose', 'Inflammatory Bowel Diseases', 'The use of laxatives is contraindicated in patients with inflammatory bowel disease.  Patients with inflammatory bowel disease may experience colonic perforation with use of stimulant laxatives.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1471, 21655, 'Lactulose', 'Inflammatory Bowel Diseases', 'The use of laxatives is contraindicated in patients with inflammatory bowel disease.  Patients with inflammatory bowel disease may experience colonic perforation with use of stimulant laxatives.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1472, 21656, 'Lactulose', 'Inflammatory Bowel Diseases', 'The use of laxatives is contraindicated in patients with inflammatory bowel disease.  Patients with inflammatory bowel disease may experience colonic perforation with use of stimulant laxatives.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1473, 26675, 'Lactulose', 'Inflammatory Bowel Diseases', 'The use of laxatives is contraindicated in patients with inflammatory bowel disease.  Patients with inflammatory bowel disease may experience colonic perforation with use of stimulant laxatives.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1474, 29352, 'Lactulose', 'Inflammatory Bowel Diseases', 'The use of laxatives is contraindicated in patients with inflammatory bowel disease.  Patients with inflammatory bowel disease may experience colonic perforation with use of stimulant laxatives.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1475, 29353, 'Lactulose', 'Inflammatory Bowel Diseases', 'The use of laxatives is contraindicated in patients with inflammatory bowel disease.  Patients with inflammatory bowel disease may experience colonic perforation with use of stimulant laxatives.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1476, 33077, 'Lactulose', 'Inflammatory Bowel Diseases', 'The use of laxatives is contraindicated in patients with inflammatory bowel disease.  Patients with inflammatory bowel disease may experience colonic perforation with use of stimulant laxatives.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1477, 7051, 'Lactulose', 'Intestinal Obstruction', 'The use of laxatives is contraindicated in patients with intestinal obstruction disorders.  Patients with intestinal obstruction disorders may need their underlying condition treated to correct the constipation.  Some laxatives require reduction in the colon to their active form to be effective which may be a problem in patients with intestinal obstruction.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1478, 7061, 'Lactulose', 'Intestinal Obstruction', 'The use of laxatives is contraindicated in patients with intestinal obstruction disorders.  Patients with intestinal obstruction disorders may need their underlying condition treated to correct the constipation.  Some laxatives require reduction in the colon to their active form to be effective which may be a problem in patients with intestinal obstruction.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1479, 10242, 'Lactulose', 'Intestinal Obstruction', 'The use of laxatives is contraindicated in patients with intestinal obstruction disorders.  Patients with intestinal obstruction disorders may need their underlying condition treated to correct the constipation.  Some laxatives require reduction in the colon to their active form to be effective which may be a problem in patients with intestinal obstruction.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1480, 17961, 'Lactulose', 'Intestinal Obstruction', 'The use of laxatives is contraindicated in patients with intestinal obstruction disorders.  Patients with intestinal obstruction disorders may need their underlying condition treated to correct the constipation.  Some laxatives require reduction in the colon to their active form to be effective which may be a problem in patients with intestinal obstruction.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1481, 17962, 'Lactulose', 'Intestinal Obstruction', 'The use of laxatives is contraindicated in patients with intestinal obstruction disorders.  Patients with intestinal obstruction disorders may need their underlying condition treated to correct the constipation.  Some laxatives require reduction in the colon to their active form to be effective which may be a problem in patients with intestinal obstruction.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1482, 18804, 'Lactulose', 'Intestinal Obstruction', 'The use of laxatives is contraindicated in patients with intestinal obstruction disorders.  Patients with intestinal obstruction disorders may need their underlying condition treated to correct the constipation.  Some laxatives require reduction in the colon to their active form to be effective which may be a problem in patients with intestinal obstruction.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1483, 21541, 'Lactulose', 'Intestinal Obstruction', 'The use of laxatives is contraindicated in patients with intestinal obstruction disorders.  Patients with intestinal obstruction disorders may need their underlying condition treated to correct the constipation.  Some laxatives require reduction in the colon to their active form to be effective which may be a problem in patients with intestinal obstruction.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1484, 21545, 'Lactulose', 'Intestinal Obstruction', 'The use of laxatives is contraindicated in patients with intestinal obstruction disorders.  Patients with intestinal obstruction disorders may need their underlying condition treated to correct the constipation.  Some laxatives require reduction in the colon to their active form to be effective which may be a problem in patients with intestinal obstruction.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1485, 21547, 'Lactulose', 'Intestinal Obstruction', 'The use of laxatives is contraindicated in patients with intestinal obstruction disorders.  Patients with intestinal obstruction disorders may need their underlying condition treated to correct the constipation.  Some laxatives require reduction in the colon to their active form to be effective which may be a problem in patients with intestinal obstruction.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1486, 21551, 'Lactulose', 'Intestinal Obstruction', 'The use of laxatives is contraindicated in patients with intestinal obstruction disorders.  Patients with intestinal obstruction disorders may need their underlying condition treated to correct the constipation.  Some laxatives require reduction in the colon to their active form to be effective which may be a problem in patients with intestinal obstruction.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1487, 21655, 'Lactulose', 'Intestinal Obstruction', 'The use of laxatives is contraindicated in patients with intestinal obstruction disorders.  Patients with intestinal obstruction disorders may need their underlying condition treated to correct the constipation.  Some laxatives require reduction in the colon to their active form to be effective which may be a problem in patients with intestinal obstruction.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1488, 21656, 'Lactulose', 'Intestinal Obstruction', 'The use of laxatives is contraindicated in patients with intestinal obstruction disorders.  Patients with intestinal obstruction disorders may need their underlying condition treated to correct the constipation.  Some laxatives require reduction in the colon to their active form to be effective which may be a problem in patients with intestinal obstruction.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1489, 26675, 'Lactulose', 'Intestinal Obstruction', 'The use of laxatives is contraindicated in patients with intestinal obstruction disorders.  Patients with intestinal obstruction disorders may need their underlying condition treated to correct the constipation.  Some laxatives require reduction in the colon to their active form to be effective which may be a problem in patients with intestinal obstruction.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1490, 29352, 'Lactulose', 'Intestinal Obstruction', 'The use of laxatives is contraindicated in patients with intestinal obstruction disorders.  Patients with intestinal obstruction disorders may need their underlying condition treated to correct the constipation.  Some laxatives require reduction in the colon to their active form to be effective which may be a problem in patients with intestinal obstruction.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1491, 29353, 'Lactulose', 'Intestinal Obstruction', 'The use of laxatives is contraindicated in patients with intestinal obstruction disorders.  Patients with intestinal obstruction disorders may need their underlying condition treated to correct the constipation.  Some laxatives require reduction in the colon to their active form to be effective which may be a problem in patients with intestinal obstruction.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1492, 33077, 'Lactulose', 'Intestinal Obstruction', 'The use of laxatives is contraindicated in patients with intestinal obstruction disorders.  Patients with intestinal obstruction disorders may need their underlying condition treated to correct the constipation.  Some laxatives require reduction in the colon to their active form to be effective which may be a problem in patients with intestinal obstruction.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1493, 7051, 'Lactulose', 'Diabetes Mellitus', 'Since lactulose solution contains galactose and lactose, it should be used cautiously in patients with diabetes.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1494, 7061, 'Lactulose', 'Diabetes Mellitus', 'Since lactulose solution contains galactose and lactose, it should be used cautiously in patients with diabetes.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1495, 10242, 'Lactulose', 'Diabetes Mellitus', 'Since lactulose solution contains galactose and lactose, it should be used cautiously in patients with diabetes.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1496, 17961, 'Lactulose', 'Diabetes Mellitus', 'Since lactulose solution contains galactose and lactose, it should be used cautiously in patients with diabetes.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1497, 17962, 'Lactulose', 'Diabetes Mellitus', 'Since lactulose solution contains galactose and lactose, it should be used cautiously in patients with diabetes.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1498, 18804, 'Lactulose', 'Diabetes Mellitus', 'Since lactulose solution contains galactose and lactose, it should be used cautiously in patients with diabetes.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1499, 21541, 'Lactulose', 'Diabetes Mellitus', 'Since lactulose solution contains galactose and lactose, it should be used cautiously in patients with diabetes.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1500, 21545, 'Lactulose', 'Diabetes Mellitus', 'Since lactulose solution contains galactose and lactose, it should be used cautiously in patients with diabetes.', '2', '', 'DDInter', 0);
